Represents 9th Exit from RiverVest Venture Fund II ST. LOUIS and CLEVELAND (April 3, 2018) – RiverVest Venture Partners today announced portfolio company Securus Medical Group, Inc., has been sold to Boston Scientific Corporation (NYSE: BSX). Boston Scientific has been an investor in Securus since 2016, and the transaction price for the remaining stake not […]
Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor MARLBOROUGH, Mass., April 3, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Securus Medical Group, Inc., a privately-held company that has developed a thermal monitoring system for the continuous measurement of esophageal temperature. Boston Scientific has been an investor in Securus […]
SOUTH SAN FRANCISCO, March 5, 2018 — Lyric Pharmaceuticals, Inc. (Lyric), a biopharmaceutical company, today announced the completion of enrollment of PROMOTE, an international, multicenter, randomized, controlled Phase 2 study of LP101 (ulimorelin) for the treatment of enteral feeding intolerance (EFI) in critically ill patients.
DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company has appointed Carl J. St. Bernard as president and chief executive officer.
— Proceeds will support advancement of AK002 in five disease areas — — Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease — SAN CARLOS, Calif., December 13, 2017– Allakos Inc., a private, clinical-stage biopharmaceutical company focused on the development of antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced […]
Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia Clinical-stage biotech granted orphan drug designation for the treatment of CAH, a rare endocrine disease San Francisco – December 4, 2017 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced that the U.S. Food […]
ST. LOUIS, MO (Oct. 25, 2017)—RiverVest Venture Partners announced today that Ronald T. Borchardt, Ph.D. and Jared Rutter, Ph.D. have joined the life science venture capital firm’s Scientific Advisory Board. Comprised of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance to the venture firm as it identifies and invests in promising biopharmaceutical […]
Clinical-stage, rare endocrine disease Company expands leadership team and advances lead candidate for congenital adrenal hyperplasia San Francisco – October 12, 2017 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today provided a corporate update, building upon a previously closed Series A financing of $20 million to expand its […]
CLEVELAND, Ohio – August 28, 2017 – Neuros Medical, Inc., a neuromodulation company, announced today the appointment of Tom Wilder as President and CEO.
Endeavour Vision and RiverVest Venture Partners Lead Funding TOLEDO, Ohio, Aug. 15, 2017 /PRNewswire/ — VentureMed Group®, Inc., (“VMG” or the “Company”) a medical device company developing and commercializing next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), today announced it had raised $15 million in new equity financing. The Series B […]
— Board of Directors appoints Robert Alexander as CEO and Adam Tomasi as COO & CFO — Allakos plans to initiate a broad, multi-indication clinical program with AK002 in 2017 SAN CARLOS, Calif., August 15, 2017 – Allakos Inc., a private, clinical-stage biopharmaceutical company focused on the development of therapeutic antibodies for the treatment of allergic, […]
CLEVELAND, Ohio – August 7, 2017 – Neuros Medical, Inc., a neuromodulation company, announced today that it has closed a $20 million Series AA venture capital financing. U.S. Venture Partners led the financing, and was joined by Boston Scientific, Aperture Venture Partners, Osage University Partners, and JumpStart, Inc.